Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

La Brea Industrial Development Company Ltd (LABIDCO) has executed an agreement with Novo Farms Ltd, making it the newest tenant on the La Brea Industrial Estate.

Omega Therapeutics is halting work on its only clinical-stage candidate as part of a strategic refocus centered on three ...

Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...

Career mobility is one of the best things about working for a large company, especially one with offices across the globe. Diego Moreno, a health economics manager at Novo Nordisk Canada Inc. (NNCI), ...

The chart below compares the forward price to earnings (P/E) ratio of AstraZeneca to multiples in a peer set of leading ...

Courts have long deferred to CMS’s decisions on implementation of laws that govern Medicare. The overturning of the Chevron ...

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

Novo Nordisk (NVO) reportedly plans to phase out production of human insulin pens while it ramps up production of other injected diabetes medications such as Ozempic. Read more.

This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...

German drugmaker Evotec is attracting takeover interest from U.S.-based Halozyme Therapeutics , Bloomberg News reported on Thursday.